PLIANT THERAPEUTICS, INC. current report, 23 January 2023

Full document

Filing Overview

Pliant Therapeutics, Inc. filed a Form 8-K dated January 23, 2023, under Item 8.01 (Other Events). The filing concerns the company’s equity financing arrangements and does not report quarterly or annual operating results.

Key Transaction and Financing Details

  • The company announced commencement of an underwritten public offering of common stock pursuant to its effective Form S-3 shelf registration statement.
  • The filing also addresses the company’s Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co., which permits at-the-market sales of common stock.
  • The related sales agreement prospectus authorized aggregate ATM offerings of up to $150.0 million.
  • No shares were sold under the Sales Agreement or related prospectus from July 2, 2021 through January 23, 2023.
  • The company terminated the Sales Agreement prospectus on January 23, 2023, while the underlying Sales Agreement remained in effect.
  • No additional shares may be sold under the Sales Agreement unless and until the company files a new sales agreement prospectus or prospectus supplement.

Financial Metrics and Liquidity

The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, share-offering size, offering price, or net proceeds. Accordingly, the filing text does not provide a clear value for these metrics.

Changes, Outlook, and Risks

  • The material change is the termination of the existing ATM sales agreement prospectus and the announced commencement of a separate underwritten public offering.
  • The filing does not provide management guidance or an operating outlook.
  • Potential dilution and financing proceeds cannot be assessed from this filing because the number of shares, offering price, gross proceeds, and net proceeds were not stated.
  • The offering remains subject to applicable registration and securities-law requirements; the Form 8-K itself is not an offer to sell or solicitation to buy securities.

Investor Verification Checklist

  • Verify the final size, pricing, number of shares, and closing status of the underwritten offering.
  • Review subsequent filings for any new ATM prospectus or prospectus supplement and any resulting share sales.
  • Assess dilution using the company’s updated shares outstanding after the offering.
  • Review the latest balance sheet and cash runway because this filing provides no liquidity data.
  • Confirm the intended use of proceeds and any related financing risks in the offering documents.